Ariel Hurley Sells 830 Shares of Blueprint Medicines Corp (NASDAQ:BPMC) Stock

Share on StockTwits

Blueprint Medicines Corp (NASDAQ:BPMC) insider Ariel Hurley sold 830 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $94.98, for a total value of $78,833.40. Following the completion of the sale, the insider now owns 830 shares in the company, valued at approximately $78,833.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Ariel Hurley also recently made the following trade(s):

  • On Monday, June 17th, Ariel Hurley sold 1,405 shares of Blueprint Medicines stock. The shares were sold at an average price of $98.22, for a total value of $137,999.10.
  • On Thursday, June 13th, Ariel Hurley sold 2,733 shares of Blueprint Medicines stock. The shares were sold at an average price of $88.04, for a total value of $240,613.32.

Shares of Blueprint Medicines stock opened at $98.24 on Friday. Blueprint Medicines Corp has a one year low of $44.58 and a one year high of $100.76. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.27. The company’s 50-day simple moving average is $91.39. The company has a market cap of $4.71 billion, a price-to-earnings ratio of -18.23 and a beta of 1.55.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($1.98) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.15). Blueprint Medicines had a negative net margin of 603.88% and a negative return on equity of 59.26%. The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.38 million. During the same quarter in the previous year, the company earned ($1.29) EPS. The firm’s revenue for the quarter was down 23.2% on a year-over-year basis. On average, analysts predict that Blueprint Medicines Corp will post -7.76 earnings per share for the current fiscal year.

A number of equities research analysts have commented on BPMC shares. BidaskClub upgraded Misonix from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 3rd. ValuEngine upgraded Ultrapar Participacoes from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 4th. Robert W. Baird initiated coverage on Blueprint Medicines in a research report on Thursday. They set an “outperform” rating on the stock. Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Monday, June 17th. Finally, Goldman Sachs Group upgraded Lenovo Group from a “neutral” rating to a “buy” rating in a research report on Thursday, May 23rd. They noted that the move was a valuation call. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $106.43.

Several institutional investors have recently made changes to their positions in BPMC. FMR LLC boosted its holdings in Blueprint Medicines by 5.3% in the first quarter. FMR LLC now owns 6,939,294 shares of the biotechnology company’s stock worth $555,491,000 after acquiring an additional 346,738 shares in the last quarter. OppenheimerFunds Inc. boosted its holdings in Blueprint Medicines by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 1,710,895 shares of the biotechnology company’s stock worth $136,957,000 after acquiring an additional 5,720 shares in the last quarter. Norges Bank bought a new position in Blueprint Medicines in the fourth quarter worth approximately $42,705,000. Eagle Asset Management Inc. boosted its holdings in Blueprint Medicines by 0.3% in the first quarter. Eagle Asset Management Inc. now owns 763,908 shares of the biotechnology company’s stock worth $61,150,000 after acquiring an additional 2,639 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Blueprint Medicines by 6.6% in the fourth quarter. Geode Capital Management LLC now owns 492,662 shares of the biotechnology company’s stock worth $26,559,000 after acquiring an additional 30,499 shares in the last quarter. Institutional investors own 97.45% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Read More: Is a Roth IRA right for you?

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
7,019 Shares in D. R. Horton Inc  Bought by Wedbush Securities Inc.
7,019 Shares in D. R. Horton Inc Bought by Wedbush Securities Inc.
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust


© 2006-2019 Ticker Report